Showing 1 - 6 results of 6 for search 'Elena Elli', query time: 0.03s Refine Results
  1. 1
    A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management

    A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management by Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani

    Published 2012-03-01
    Get full text
    Article
  2. 2
    A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management

    A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management by Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani

    Published 2012-01-01
    Get full text
    Article
  3. 3
    PB2004: CHRONIC MYELOMONOCYTIC LEUKEMIA AND CONCOMITANT MONOCLONAL GAMMOPATHY: A MULTICENTRE RETROSPECTIVE STUDY OF CLINICAL CHARACTERISTICS, PREVALENCE AND OUTCOME

    PB2004: CHRONIC MYELOMONOCYTIC LEUKEMIA AND CONCOMITANT MONOCLONAL GAMMOPATHY: A MULTICENTRE RETROSPECTIVE STUDY OF CLINICAL CHARACTERISTICS, PREVALENCE AND OUTCOME by Elisa Diral, Gregorio Maria Bergonzi, Elena Elli, Fabrizio Cavalca, Stefano Crippa, Lorenzo Rizzo, Marta Riva, Fabio Ciceri, Massimo Stefano Luca Bernardi

    Published 2023-08-01
    Get full text
    Article
  4. 4
    GOOD OUTCOME FOR VERY HIGH RISK ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA CARRYING GENETIC ABNORMALITIES t(4;11)(q21;q23) or t(9;22)(q34;q11), IF PROMPTLY SUBMITTED TO ALLOGENEIC TRANSPLANTATION, AFTER OBTAINING A GOOD MOLECULAR REMISSION.

    GOOD OUTCOME FOR VERY HIGH RISK ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA CARRYING GENETIC ABNORMALITIES t(4;11)(q21;q23) or t(9;22)(q34;q11), IF PROMPTLY SUBMITTED TO ALLOGENEIC... by Matteo Parma, Clara Vigano', Monica Fumagalli, Federica Colnaghi, Arianna Colombo, Federica Mottadelli, Vincenzo Rossi, Elena Elli, Elisabetta Terruzzi, Angelo Belotti, Giovanni Cazzaniga, Enrico Maria Pogliani, Pietro Pioltelli

    Published 2015-05-01
    Get full text
    Article
  5. 5
    Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

    Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments by Valerio De Stefano, Tommaso Za, Elena Rossi, Alessandro M. Vannucchi, Marco Ruggeri, Elena Elli, Caterina Micò, Alessia Tieghi, Rossella R. Cacciola, Cristina Santoro, Giancarla Gerli, Nicola Vianelli, Paola Guglielmelli, Lisa Pieri, Francesca Scognamiglio, Francesco Rodeghiero, Enrico M. Pogliani, Guido Finazzi, Luigi Gugliotta, Roberto Marchioli, Giuseppe Leone, Tiziano Barbui

    Published 2008-03-01
    Get full text
    Article
  6. 6
    Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

    Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients by Margherita Maffioli, Toni Giorgino, Barbara Mora, Alessandra Iurlo, Elena Elli, Maria Chiara Finazzi, Marianna Caramella, Elisa Rumi, Maria Cristina Carraro, Nicola Polverelli, Mariella D'Adda, Simona Malato, Marianna Rossi, Alfredo Molteni, Alessandro Vismara, Cinzia Sissa, Francesco Spina, Michela Anghilieri, Daniele Cattaneo, Rossella Renso, Marta Bellini, Maria Luisa Pioltelli, Chiara Cavalloni, Daniela Barraco, Raffaella Accetta, Lorenza Bertù, Matteo Giovanni Della Porta, Francesco Passamonti

    Published 2019-11-01
    Get full text
    Article

Search Tools: